SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY)
INCY 106.00+0.8%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (3004)12/10/2013 2:40:30 PM
From: tuck  Read Replies (2) of 3202
 
"An exploratory analysis of data collected over five years in the ongoing Phase II trial offers evidence that Jakafi may stabilize or improve bone marrow fibrosis in patients with myelofibrosis"

I couldn't find this parsing the abstracts. Seems as though ASH has made searching harder. Anyhow, the last reported reversal rate was 22% (EHA, ASCO), with stabilization ~55%, if memory serves. As you point out in the prior post, Geron's results don't seem to beat that.

Thanks for keeping us up to date!

Cheers, Tuck

Edit: Found it working from the Incyte PR:

Kvasnicka

See figure 1b. Looks good. Do we know how important this metric is? 15% @ 24 months, 34% @ 48 months, and 36% at 60 months. At what month was the 18% figure for Geron recorded?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News